Prediction - RAC will have legendary unicorn-like status among drug-development biotechs?, page-4

I no longer believe in Santa clause but I still get that feeling in the morning when I see a new thread by @wombat777 thanks for your analysis, especially your ability to put things into context.

@SMN888 if Bisantrene’s efficacy becomes undeniable you raise a good point on a price ceiling which RAC wouldn’t see fair value. The way I see it if Bisantrene becomes this unicorn then we need to also risk short term for long term gain like the buyer. In this scenario a reduced upfront buy-out in the $20-30b range plus royalties of 10% would allow us future exposure of the upside, which could expose us to further 10’s of billions in profit over the next decade